# ZYMEWORKS INC. (ZYME) FY2026 YTD Q2 P&L / Income Statement

- Company: ZYMEWORKS INC. (ZYME)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001937653-26-000047
- Page: https://plicit.ai/financials/zyme/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/zyme-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Partner

Income statement for 2026-01-01 through 2026-06-30. View: Partner. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Research and development collaborations**: 6,998,000 US dollars
- **Total operating expenses**: 96,296,000 US dollars
- **Loss from operations**: negative 89,298,000 US dollars
- **Other income (expense), net (calculated)**: negative 2,347,000 US dollars
- **(Loss) income before income taxes**: negative 91,645,000 US dollars
- **Income tax recovery (expense)**: negative 2,464,000 US dollars
- **Net (loss) income**: negative 89,181,000 US dollars
- **Jazz - Development support payments**: 683,000 US dollars
- **Jazz - Drug supply for ongoing studies**: 1,136,000 US dollars
- **Jazz - Other drug supply**: 162,000 US dollars
- **Jazz - Royalties**: 2,919,000 US dollars
- **BeOne - Drug supply**: 1,664,000 US dollars
- **BeOne - Royalties**: 434,000 US dollars
- **Research and development**: 61,892,000 US dollars
- **General and administrative**: 34,404,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.